

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ustekinumab for treating active psoriatic arthritis (Rapid Review of TA313)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|-------------------------------------------------------------------------------------------------------------------------------|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|-------------------------------------------------------------------------------------------------------------------------------|

Not applicable

- | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

No equality issues were raised by the company or ERG that needed to be addressed by the Committee in this rapid review.

- | |
|----------------------------------------------------------------------------------------------------------------------------------|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------|

The Committee noted that some people may have physical, sensory or learning disabilities or communication difficulties that could affect their responses to components of the Psoriatic Arthritis Response Criteria (PsARC). It concluded that this should be taken into account when using the PsARC. The draft recommendations include this consideration.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Some people may have physical, sensory or learning disabilities or communication difficulties that could affect their responses to components of the PsARC, which may affect the decision to continue ustekinumab treatment after week 24. The draft recommendations state that clinicians should take this into account when using the PsARC.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No further recommendations or explanations are needed.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The Committee's considerations of equality issues are described in section 4.17 and 4.23 of the appraisal consultation document. The recommendation to take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC is described in section 1.3.

Approved by Associate Director (name): Helen Knight

Date: 01/12/2014

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional equality issues have been raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable; the recommendations have not changed after consultation.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable; the recommendations have not changed after consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable; the recommendations have not changed after consultation.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's considerations of equality issues are described in section 4.16 and 4.22 of the final appraisal determination. The recommendation to take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC is described in section 1.3.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 03/03/2015